Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$11.2 - $16.97 $1.03 Million - $1.56 Million
-92,000 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$12.36 - $18.28 $1.14 Million - $1.68 Million
92,000 New
92,000 $1.22 Million

Others Institutions Holding KALV

About KalVista Pharmaceuticals, Inc.


  • Ticker KALV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,602,000
  • Market Cap $281M
  • Description
  • KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...
More about KALV
Track This Portfolio

Track Mangrove Partners Portfolio

Follow Mangrove Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mangrove Partners, based on Form 13F filings with the SEC.

News

Stay updated on Mangrove Partners with notifications on news.